- Home
- ADVM vs LPSN Comparison
ADVM vs LPSN Comparison
Compare ADVM & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- LPSN
- Stock Information
- Founded
- ADVM 2006
- LPSN 1995
- Country
- ADVM United States
- LPSN United States
- Employees
- ADVM N/A
- LPSN N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- LPSN EDP Services
- Sector
- ADVM Health Care
- LPSN Technology
- Exchange
- ADVM Nasdaq
- LPSN Nasdaq
- Market Cap
- ADVM 141.9M
- LPSN 101.6M
- IPO Year
- ADVM 2014
- LPSN 2000
- Fundamental
- Price
- ADVM $6.76
- LPSN $1.04
- Analyst Decision
- ADVM Strong Buy
- LPSN Hold
- Analyst Count
- ADVM 6
- LPSN 6
- Target Price
- ADVM $28.17
- LPSN $1.18
- AVG Volume (30 Days)
- ADVM 163.1K
- LPSN 3.4M
- Earning Date
- ADVM 08-12-2024
- LPSN 07-31-2024
- Dividend Yield
- ADVM N/A
- LPSN N/A
- EPS Growth
- ADVM N/A
- LPSN N/A
- EPS
- ADVM N/A
- LPSN N/A
- Revenue
- ADVM N/A
- LPSN $361,824,000.00
- Revenue This Year
- ADVM N/A
- LPSN N/A
- Revenue Next Year
- ADVM $5,848.83
- LPSN N/A
- P/E Ratio
- ADVM N/A
- LPSN N/A
- Revenue Growth
- ADVM N/A
- LPSN N/A
- 52 Week Low
- ADVM $6.38
- LPSN $0.45
- 52 Week High
- ADVM $29.70
- LPSN $4.74
- Technical
- Relative Strength Index (RSI)
- ADVM 43.95
- LPSN 40.09
- Support Level
- ADVM $6.64
- LPSN $1.24
- Resistance Level
- ADVM $7.00
- LPSN $1.34
- Average True Range (ATR)
- ADVM 0.40
- LPSN 0.14
- MACD
- ADVM -0.00
- LPSN -0.06
- Stochastic Oscillator
- ADVM 19.61
- LPSN 3.85
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation.. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.